No description available.

The signaling pathways of tyrosine kinase Trk receptors and their downstream biological effects are well known, but the parameters controlling the interactions between the receptors and their natural ligands still remain to be defined. Recent published reports from our laboratory indicate that nerve growth factor (NGF)-induced TrkA receptor activation is dependent on a membrane cellular sialidase. This sialidase activity specifically targets and hydrolyzes sialyl α-2, 3-linked β-galactosyl residues resulting in the desialylation and activation of the receptor. These findings support a novel hypothesis that places mammalian sialidase(s) in a cycle of activation of these receptors by their natural ligand. Taken together, they also predict a prerequisite desialylation of Trk receptors caused by a sialidase on the cell surface enabling the removal of a steric hindrance to receptor dimerization. Until now, the sialidase associated with neurotrophin-treated live Trk-expressing cells has not been identified. The molecular mechanism(s) of sialidase activation by neurotrophin factors binding to their receptors also remains unknown. In this thesis, the novel role of Neu1 sialidase in the activation of ligand-induced TrkA and TrkB receptors has been identified. It has been reported for the first time that Neu1 is already in complex with naïve and ligand-induced Trk receptors. In addition, a membrane sialidase mechanism initiated by NGF binding to TrkA has been indentified. It suggests a potentiation of GPCR-signaling via membrane Gαi subunit proteins and matrix metalloproteinase-9 (MMP-9) activation to induce Neu1 sialidase activation in live TrkA- and TrkB-expressing cells and primary neurons. These results establish a unique mode of regulation of Trk receptors by their natural ligand and define a new function for Neu1 sialidase. Preliminary data indicate that members of the family of tyrosine kinase receptors like epidermal growth factor receptor (EGFR) and insulin receptor are also under the same regulatory control of Neu1 sialidase. Recent reports from the laboratory have indicated that ligand-induced activation of the highly glycosylated Toll-like receptors, TLR-2,-3 and -4 is also dependent on Neu1 sialidase on the cell surface. Taken all together, the findings in this thesis uncover a Neu1 and MMP-9 cross-talk on the cell surface which is critically essential for neurotrophin-induced Trk tyrosine kinase receptor activation and neuron function. / Thesis (Ph.D, Microbiology & Immunology) -- Queen's University, 2010-04-26 11:44:51.418

Tie1 é um receptor tirosina quinase expresso em células endoteliais importante em angiogênese, formação de vasos sanguíneos a partir de vasos pré-existentes. Este receptor pertence a uma família pequena composta por apenas dois membros (Tie1 e Tie2) para os quais angiopoietinas foram identificadas como ligantes de Tie2. No entanto, Tie1 continua a ser um receptor órfão, sem ligantes identificados até o momento. Sendo assim, é difícil compreender completamente as propriedades biológicas de Tie1 e seus mecanismos moleculares em angiogênese sem um ligante identificado. Entretanto, como sugerido através de estudos de deleção gênica, este receptor é uma molécula essencial na angiogênese, apresentando um papel importante no desenvolvimento da vascularização da retina e desenvolvimento de tumores. O nosso objetivo foi estudar a participação do domínio extracelular de Tie1 na neovascularização e, no processo, identificar possíveis ligantes para este receptor. Através da tecnologia de phage display, identificamos um peptídeo específico e seletivo para Tie1, sugerindo a existência de um sítio de ligação único neste receptor. Mostramos que este peptídeo é capaz de inibir a proliferação de células endoteliais induzida por Ang1, um ligante bem caracterizado de Tie2 que também modula a atividade de Tie1. Além disso, também mostramos que este peptídeo inibe a angiogênese in vivo num modelo animal bastante relevante para estudo de doenças humanas, o modelo da retinopatia induzida por oxigênio. Uma vez que este peptídeo liga-se a um sítio único e seletivo para Tie1, hipotetizamos que o mesmo poderia mimetizar possíveis ligantes naturais deste receptor. Para identificá-los, proteínas com mimetopo cruzado com este peptídeo foram identificadas em extrato proteico de diferentes linhagens celulares. Tais proteínas são possíveis candidatos a interação com Tie1. Em resumo, demonstramos que o domínio extracelular de Tie1 é importante para a angiogênese patológica e identificamos proteínas como possíveis ligantes deste receptor, o que poderá contribuir para um melhor entendimento da participação de Tie1 na formação de vasos. O peptídeo aqui identificado poderá ser ainda uma ferramenta útil para o desenvolvimento de novas terapias anti-angiogênicas com importantes aplicações à saúde humana. / Tie1 is a tyrosine kinase receptor expressed by endothelial cells and important in angiogenesis, the formation of new blood vessels from pre-existing ones. This receptor belongs to a small family of receptors composed of two members only (Tie1 and Tie2) to which angiopoietins have been identified as ligands for Tie2. On the other hand, Tie1 is still an orphan receptor with no ligand identified to date. Thus, it is difficult to assess Tie1 mechanism of action in neovascularization without a known ligand. Nevertheless, gene deletion studies have shown that Tie1 is essential in angiogenesis, and plays an important role in retinal and tumoral vascularization. The aim of our study was to evaluate the participation of Tie1 extracellular domain in angiogenesis, and in the process, to identify putative ligands for this receptor. Utilizing phage display, we have identified and characterized a Tie1 specific and selective ligand peptide, which suggests the existence of a binding site unique to this receptor and not shared by other family members. We show that this peptide prevents endothelial cells proliferation, induced by angiopoetin-1, a ligand for Tie2 but which also modulates Tie1 activity. Using a well-accepted mouse model for human diseases, the oxygen induced retinopathy model, we show that this peptide inhibits angiogenesis in vivo. Since this peptide maps to a unique binding site in Tie1, we hypothesized that it might mimic a natural ligand for this receptor. To identify them, proteins with cross reactive epitopes with an anti-peptide sera were identified by proteomic approaches. These proteins are thus possible ligands for Tie1. In summary, we have shown that Tie1 extracellular domain is important in angiogenesis and we have identified putative ligand for this receptor, which might contribute to a better understanding of the molecular mechanisms associated with Tie1 in blood vessel formation. The peptide here characterized may also be an important tool for the development of novel anti-angiogenesis therapeutic approaches for disesase with an angiogenic component.

Tie1 é um receptor tirosina quinase expresso em células endoteliais importante em angiogênese, formação de vasos sanguíneos a partir de vasos pré-existentes. Este receptor pertence a uma família pequena composta por apenas dois membros (Tie1 e Tie2) para os quais angiopoietinas foram identificadas como ligantes de Tie2. No entanto, Tie1 continua a ser um receptor órfão, sem ligantes identificados até o momento. Sendo assim, é difícil compreender completamente as propriedades biológicas de Tie1 e seus mecanismos moleculares em angiogênese sem um ligante identificado. Entretanto, como sugerido através de estudos de deleção gênica, este receptor é uma molécula essencial na angiogênese, apresentando um papel importante no desenvolvimento da vascularização da retina e desenvolvimento de tumores. O nosso objetivo foi estudar a participação do domínio extracelular de Tie1 na neovascularização e, no processo, identificar possíveis ligantes para este receptor. Através da tecnologia de phage display, identificamos um peptídeo específico e seletivo para Tie1, sugerindo a existência de um sítio de ligação único neste receptor. Mostramos que este peptídeo é capaz de inibir a proliferação de células endoteliais induzida por Ang1, um ligante bem caracterizado de Tie2 que também modula a atividade de Tie1. Além disso, também mostramos que este peptídeo inibe a angiogênese in vivo num modelo animal bastante relevante para estudo de doenças humanas, o modelo da retinopatia induzida por oxigênio. Uma vez que este peptídeo liga-se a um sítio único e seletivo para Tie1, hipotetizamos que o mesmo poderia mimetizar possíveis ligantes naturais deste receptor. Para identificá-los, proteínas com mimetopo cruzado com este peptídeo foram identificadas em extrato proteico de diferentes linhagens celulares. Tais proteínas são possíveis candidatos a interação com Tie1. Em resumo, demonstramos que o domínio extracelular de Tie1 é importante para a angiogênese patológica e identificamos proteínas como possíveis ligantes deste receptor, o que poderá contribuir para um melhor entendimento da participação de Tie1 na formação de vasos. O peptídeo aqui identificado poderá ser ainda uma ferramenta útil para o desenvolvimento de novas terapias anti-angiogênicas com importantes aplicações à saúde humana. / Tie1 is a tyrosine kinase receptor expressed by endothelial cells and important in angiogenesis, the formation of new blood vessels from pre-existing ones. This receptor belongs to a small family of receptors composed of two members only (Tie1 and Tie2) to which angiopoietins have been identified as ligands for Tie2. On the other hand, Tie1 is still an orphan receptor with no ligand identified to date. Thus, it is difficult to assess Tie1 mechanism of action in neovascularization without a known ligand. Nevertheless, gene deletion studies have shown that Tie1 is essential in angiogenesis, and plays an important role in retinal and tumoral vascularization. The aim of our study was to evaluate the participation of Tie1 extracellular domain in angiogenesis, and in the process, to identify putative ligands for this receptor. Utilizing phage display, we have identified and characterized a Tie1 specific and selective ligand peptide, which suggests the existence of a binding site unique to this receptor and not shared by other family members. We show that this peptide prevents endothelial cells proliferation, induced by angiopoetin-1, a ligand for Tie2 but which also modulates Tie1 activity. Using a well-accepted mouse model for human diseases, the oxygen induced retinopathy model, we show that this peptide inhibits angiogenesis in vivo. Since this peptide maps to a unique binding site in Tie1, we hypothesized that it might mimic a natural ligand for this receptor. To identify them, proteins with cross reactive epitopes with an anti-peptide sera were identified by proteomic approaches. These proteins are thus possible ligands for Tie1. In summary, we have shown that Tie1 extracellular domain is important in angiogenesis and we have identified putative ligand for this receptor, which might contribute to a better understanding of the molecular mechanisms associated with Tie1 in blood vessel formation. The peptide here characterized may also be an important tool for the development of novel anti-angiogenesis therapeutic approaches for disesase with an angiogenic component.

O objetivo deste trabalho foi avaliar a eficácia do mesilato de imatinibe, em comparação com a quimioterapia usual com vimblastina e prednisona, no tratamento do mastocitoma canino e descrever os efeitos colaterais apresentados pelas medicações. Bem como analisar a expressão do VEGF (fator de crescimento endotelial), a relação da expressão do gene c-kit por RT-PCR e marcação imunoistoquímica do KIT com a presença de mutações na justamembrana e a relação desta mutação com a resposta à terapia. Para tanto foram incluídos 29 animais com diagnóstico citológico de mastocitoma, estes animais foram submetidos a tomografia computadorizada para determinação das medidas das formações cutâneas e em seguida divididos em 2 grupos. O grupo 1 foi tratado com o protocolo quimioterápico de vimblastina e prednisona por 12 semanas e o grupo 2 com o mesilato de imatinibe na dose de 10 mg/Kg a cada 24 horas por 8 semanas. A avaliação da resposta ao tratamento foi realizada com mensurações periódicas das formações com paquímetro e nova tomografia ao final do tratamento para mensuração do maior diâmetro e volume tumoral. Um fragmento das formações cutâneas foi coletado antes do início do tratamento para graduação histológica da neoplasia, determinação do índice mitótico e imunomarcação para KIT, VEGF e Ki- 67. Parte do material coletado teve o DNA e RNA extraídos e posterior sequenciamento dos exons 11 do gene c-kit e determinação da expressão deste e do seu ligante por RT-PCR. A toxicidade a medicação foi avaliada segundo as normas do VCOG 1.1.A taxa de resposta do grupo VP foi de 7,7 % e no grupo MI de 28,6%, embora os pacientes tratados com mesilato de imatinibe tenham apresentado maior chance de resposta a terapia, não foi observado diferença entre os dois grupos. Os dois protocolos foram bem tolerados, os pacientes do grupo MI d menor número de efeitos colaterais. O grau histológico, Indice mitótico, padrão imunohistoquimico do KIT, além da quantificação do ki-67 foram homogêneos nos dois grupos e não influenciaram na resposta ao tratamento. A quantificação do VEGF foi mais intensa nos pacientes com remissão parcial e total. Não foi observado relação entre a quantificação do KIT e a expressão do gene c-kit, que foi maior nos pacientes que responderam ao tratamento, porém a associação desta com a resposta a terapia não pode ser determinada. Mutações ativantes no exon11 do gene c-kit não foram identificadas. O tratamento com o mesilato de imatinibe é bem tolerado pelos animais, no entanto este não se mostrou superior ao protocolo padrão de quimioterapia para o tratamento do mastocitoma; este resultado pode ter sido influenciado pelo número de animais incluídos no estudo. Mutações em outros domínios do receptor KIT e a ação do ITK em receptores como do PDGF e o VEGF podem estar relacionados a resposta a esta classe de fármacos observada neste estudo, a despeito da ausência de mutações ativantes no exon 11 do gene c-kit. / The objective of this study was to evaluate the efficacy of imatinib mesylate, compared with the usual chemotherapy with vinblastine and prednisone in the treatment of canine mast cell tumor and describe the side effects submitted by medications. Well as analyzing the expression of VEGF (vascular endothelial growth factor), the relationship between the expression of c-kit gene by RT-PCR and immunohistochemical staining of KIT with the presence of mutations in the juxtamembrane and the relationship of this mutation with response to therapy. For both 29 animals with cytological diagnosis of mast cell tumor were included, these animals underwent computed tomography to determine the measured skin formations and then divided into 2 groups. Group 1 was treated with the chemotherapeutic protocol vinblastine and prednisone for 12 weeks and the second group with the imatinib mesylate in a dose of 10 mg / kg every 24 hours for 8 weeks. The assessment of response to treatment was performed with periodic measurements of the formations Caliper and a new computed tomography in the end of treatment to measure the largest tumor diameter and volume. A fragment of skin formations was collected before the initiation of treatment for histological grading, determination of mitotic index, KIT and VEGF staining patterns and the proliferation marker Ki67. Part of the collected material was extracted RNA and DNA and subsequent sequencing of 11 exons of the c-kit gene and determination and expression of its ligand by RT-PCR. The medication toxicity was evaluated according to the standards of VCOG 1.1.A response rate of the VP group was 7.7% and 28.6% MI group, although patients treated with imatinib had a higher chance of response therapy, no difference in response between the two groups was observed. The two protocols were well tolerated, patients in the MI group had a smaller number of side effects. The histological grade, mitotic index, staining patterns KIT, beyond the quantification of Ki-67 were homogeneous in both groups and did not influence the response to treatment. Quantification of VEGF was intensely in patients with partial and total remission. It was no relationship between KIT and quantification of the expression of c-kit gene, which was higher in patients who responded to treatment, but its association with response to therapy cant be determined. Exon11 activating mutations in the c-kit gene were not identified. Treatment with imatinib mesylate is well tolerated by the animals, however this was not superior to standard chemotherapy protocol for the treatment of mast cell tumors; this result may have been influenced by the number of animals included in the study. Mutations in other domains of the KIT receptor and action in ITK receptors as PDGF and VEGF may be related to response to this class of drugs in this study, despite the absence of activating mutations in exon 11 of c-kit gene.

O objetivo deste trabalho foi avaliar a eficácia do mesilato de imatinibe, em comparação com a quimioterapia usual com vimblastina e prednisona, no tratamento do mastocitoma canino e descrever os efeitos colaterais apresentados pelas medicações. Bem como analisar a expressão do VEGF (fator de crescimento endotelial), a relação da expressão do gene c-kit por RT-PCR e marcação imunoistoquímica do KIT com a presença de mutações na justamembrana e a relação desta mutação com a resposta à terapia. Para tanto foram incluídos 29 animais com diagnóstico citológico de mastocitoma, estes animais foram submetidos a tomografia computadorizada para determinação das medidas das formações cutâneas e em seguida divididos em 2 grupos. O grupo 1 foi tratado com o protocolo quimioterápico de vimblastina e prednisona por 12 semanas e o grupo 2 com o mesilato de imatinibe na dose de 10 mg/Kg a cada 24 horas por 8 semanas. A avaliação da resposta ao tratamento foi realizada com mensurações periódicas das formações com paquímetro e nova tomografia ao final do tratamento para mensuração do maior diâmetro e volume tumoral. Um fragmento das formações cutâneas foi coletado antes do início do tratamento para graduação histológica da neoplasia, determinação do índice mitótico e imunomarcação para KIT, VEGF e Ki- 67. Parte do material coletado teve o DNA e RNA extraídos e posterior sequenciamento dos exons 11 do gene c-kit e determinação da expressão deste e do seu ligante por RT-PCR. A toxicidade a medicação foi avaliada segundo as normas do VCOG 1.1.A taxa de resposta do grupo VP foi de 7,7 % e no grupo MI de 28,6%, embora os pacientes tratados com mesilato de imatinibe tenham apresentado maior chance de resposta a terapia, não foi observado diferença entre os dois grupos. Os dois protocolos foram bem tolerados, os pacientes do grupo MI d menor número de efeitos colaterais. O grau histológico, Indice mitótico, padrão imunohistoquimico do KIT, além da quantificação do ki-67 foram homogêneos nos dois grupos e não influenciaram na resposta ao tratamento. A quantificação do VEGF foi mais intensa nos pacientes com remissão parcial e total. Não foi observado relação entre a quantificação do KIT e a expressão do gene c-kit, que foi maior nos pacientes que responderam ao tratamento, porém a associação desta com a resposta a terapia não pode ser determinada. Mutações ativantes no exon11 do gene c-kit não foram identificadas. O tratamento com o mesilato de imatinibe é bem tolerado pelos animais, no entanto este não se mostrou superior ao protocolo padrão de quimioterapia para o tratamento do mastocitoma; este resultado pode ter sido influenciado pelo número de animais incluídos no estudo. Mutações em outros domínios do receptor KIT e a ação do ITK em receptores como do PDGF e o VEGF podem estar relacionados a resposta a esta classe de fármacos observada neste estudo, a despeito da ausência de mutações ativantes no exon 11 do gene c-kit. / The objective of this study was to evaluate the efficacy of imatinib mesylate, compared with the usual chemotherapy with vinblastine and prednisone in the treatment of canine mast cell tumor and describe the side effects submitted by medications. Well as analyzing the expression of VEGF (vascular endothelial growth factor), the relationship between the expression of c-kit gene by RT-PCR and immunohistochemical staining of KIT with the presence of mutations in the juxtamembrane and the relationship of this mutation with response to therapy. For both 29 animals with cytological diagnosis of mast cell tumor were included, these animals underwent computed tomography to determine the measured skin formations and then divided into 2 groups. Group 1 was treated with the chemotherapeutic protocol vinblastine and prednisone for 12 weeks and the second group with the imatinib mesylate in a dose of 10 mg / kg every 24 hours for 8 weeks. The assessment of response to treatment was performed with periodic measurements of the formations Caliper and a new computed tomography in the end of treatment to measure the largest tumor diameter and volume. A fragment of skin formations was collected before the initiation of treatment for histological grading, determination of mitotic index, KIT and VEGF staining patterns and the proliferation marker Ki67. Part of the collected material was extracted RNA and DNA and subsequent sequencing of 11 exons of the c-kit gene and determination and expression of its ligand by RT-PCR. The medication toxicity was evaluated according to the standards of VCOG 1.1.A response rate of the VP group was 7.7% and 28.6% MI group, although patients treated with imatinib had a higher chance of response therapy, no difference in response between the two groups was observed. The two protocols were well tolerated, patients in the MI group had a smaller number of side effects. The histological grade, mitotic index, staining patterns KIT, beyond the quantification of Ki-67 were homogeneous in both groups and did not influence the response to treatment. Quantification of VEGF was intensely in patients with partial and total remission. It was no relationship between KIT and quantification of the expression of c-kit gene, which was higher in patients who responded to treatment, but its association with response to therapy cant be determined. Exon11 activating mutations in the c-kit gene were not identified. Treatment with imatinib mesylate is well tolerated by the animals, however this was not superior to standard chemotherapy protocol for the treatment of mast cell tumors; this result may have been influenced by the number of animals included in the study. Mutations in other domains of the KIT receptor and action in ITK receptors as PDGF and VEGF may be related to response to this class of drugs in this study, despite the absence of activating mutations in exon 11 of c-kit gene.

Les acides biliaires sont cruciaux pour l’absorption intestinale des lipides et ils représentent une voie majeure d’élimination du cholestérol. À concentration élevée, ils sont cytotoxiques et potentiellement carcinogènes. Il est donc essentiel de maintenir des niveaux adéquats afin de préserver une homéostasie optimale. Le récepteur nucléaire FXR est grandement impliqué dans cette régulation, en étant activé par les acides biliaires qui agissent comme ligands et en régulant les gènes nécessaires à leur synthèse et leur métabolisme. FXR est aussi impliqué dans le métabolisme lipidique et glucidique, tout en ayant un rôle anti-inflammatoire et antiprolifératif. Les mécanismes régulant l’expression et l’activité transcriptionnelle de FXR sont toutefois peu connus. Leur caractérisation pourrait mener à l’identification de nouvelles cibles thérapeutiques pour les pathologies associées au syndrome métabolique. L’activation des récepteurs nucléaires peut se faire également de façon indépendante du ligand, soit via les modifications post-transcriptionnelles. Celles-ci permettent l’intégration d’une panoplie de signaux extracellulaires et l’adaptation de la réponse transcriptionnelle des récepteurs nucléaires aux variations de conditions cellulaires. La SUMOylation et l’ubiquitination sont deux modifications pouvant affecter la localisation cellulaire des récepteurs, leur interaction avec des partenaires protéiques, l’affinité de liaison au ligand, à l’ADN, leur dimérisation, la dégradation de leurs cibles et l’arrêt de la transcription. Étant donné le rôle important des modifications post-traductionnelles des récepteurs nucléaires en réponse aux divers signaux cellulaires, nous nous sommes intéressés particulièrement à leur impact sur la dégradation et l’activité transcriptionnelle de FXR. Nos études nous ont permis d’identifier et de caractériser un nouveau site de SUMOylation de FXR, impliqué dans la régulation du récepteur. Le résidu lysine responsable de conjuguer la protéine SUMO est localisé dans un motif non-consensus de SUMOylation, prénommé pSuM, qui est sous le contrôle de la phosphorylation d’un résidu serine régulé par la kinase CK2. Nous avons également déterminé que la modification de FXR par SUMO-2 permet le recrutement de l’ubiquitine E3-ligase SUMO-dépendante RNF4, qui induit l’ubiquitination et la dégradation de FXR. Cette cascade de signalisation est nécessaire pour l’activation transcriptionnelle de FXR et pour la régulation de l’expression des gènes cibles. Elle permet de contrôler ses niveaux protéiques de façon très dynamique et d’assurer ainsi une homéostasie optimale. Dans la deuxième étude, nous identifions un nouveau signal régulant l’activité transcriptionnelle de FXR. Les récepteurs tyrosine kinase de la famille EGFR/ErbB sont connus pour activer plusieurs voies de signalisation favorisant la croissance et la prolifération cellulaire. Cependant, leur expression et activité sont souvent altérées dans différents cancers, menant à une prolifération tumorale soutenue et dérégulée. Nous démontrons que l’activation des récepteurs de la famille EGFR/ErbB mène à la répression de l’activité transcriptionnelle de FXR en induisant la SUMOylation de FXR sur des résidus lysines situés dans des sites consensus de FXR. Étant donné le rôle antiprolifératif de FXR, l’impact répresseur des récepteurs ErbB sur l’activité de FXR pourrait contribuer à leur potentiel tumorigénique. Nos résultats approfondissent notre compréhension des mécanismes de régulation de l’expression et de l’activité de FXR. Étant donné son rôle important dans le métabolisme énergétique, la réponse transcriptionnelle de FXR doit être adaptée efficacement aux variations des conditions cellulaires dans un processus de régulation homéostatique. Les modifications post-traductionnelles assurent une régulation dynamique de l’activité de FXR et leur dérégulation pourrait être impliquée dans les pathologies associées au syndrome métabolique. / Bile acids are crucial for the absorption of intestinal lipids, and are directly involved in the efflux pathway to eliminate cholesterol. At high concentrations, bile acids are cytotoxic and potentially carcinogenic. It is therefore essential to maintain bile acids to adequate levels in order to preserve optimal homeostasis. Nuclear receptor FXR is directly involved in bile acid homeostasis by being activated by bile acids to regulate critical genes required for their synthesis and their metabolism. FXR is also involved in lipid and glucose metabolism, as well as having anti-inflammatory and anti-proliferative roles. However, the exact mechanisms regulating the degradation and activity of FXR are not well understood. Therefore, elucidation of FXR activity and response to cellular signals is essential to develop novel strategies and therapeutic targets for pathologies associated with the metabolic syndrome. Besides ligand activation, nuclear receptor can be regulated in a ligand-independent manner, mainly via post-translational modifications. Such modifications are important to allow homeostatic integration of diverse extracellular signals to ensure adaptation and transcriptional response of nuclear receptors. Among them, SUMOylation and ubiquitination are two modifications that modulate cellular localization of receptors, their interaction with protein partners, ligand binding and sensitivity, DNA affinity, receptor dimerisation, stability of their targets and transcriptional dynamics. Because of the important role of post-translational modifications in nuclear receptor function, we therefore study their specific impact in respect to FXR regulation and transcriptional competence. In this study, we have identified and characterized a new and non-consensus SUMOylation site involved in the regulation of FXR activity. This site, termed pSuM for phosphorylation-dependent SUMOylation motif, consists of a targeted lysine residue that conjugates SUMO proteins under the control of kinase CK2-mediated phosphorylation. We also determined that such modification of FXR with SUMO-2 induced the recruitment of SUMO-dependent E3 ligase RNF4, resulting in FXR ubiquitination and degradation. We demonstrate that this signaling cascade involving CK2 and RNF4 is required for FXR transcriptional activation and regulation of target gene expression. Our findings identify a cellular pathway that allows a dynamic control of FXR function to ensure efficient bile acid and energy metabolism in cells. In the second study, we identify a novel cellular signal that regulates FXR activity. Tyrosine kinase receptors of the EGFR/ErbB family are well known to participate in many signaling pathways, promoting cell growth and proliferation. Aberrant expression and activity of ErbB receptors are often associated to various cancers, leading to deregulated proliferation of tumors. Here, we show that ErbB activation leads to repression of FXR transcriptional activity by inducing FXR phosphorylation and specific SUMOylation at consensus sites. Because of the antiproliferative role of FXR, the negative impact of ErbB receptors on FXR transcriptional activity is thought to contribute to their tumorigenic potential. Altogether, our results expand our understanding of the mechanisms regulating FXR expression and activity. Because of its important role in lipid and energy metabolism, the transcriptional response of FXR needs to be efficiently adapted to variations of cellular conditions in order to achieve essential homeostatic control. As such, post-translational modifications ensure a dynamic regulation of FXR activity and their pathologic deregulation may be involved in diverse diseases associated with metabolic syndrome.

Neureguline (NDF, Heregulin, GGF ARIA, oder SMDF) sind EGF-ähnliche, extrazelluläre Signalmoleküle, die mit transmembranären Tyrosinkinaserezeptoren der ErbB-Familie interagieren. Neuregulin-1/ErbB Signale steuern während der Embryonalentwicklung und im adulten Organismus vielfältige zelluläre Prozesse, wie z. B. Proliferation, Migration und Differenzierung. In der vorliegenden Arbeit wurde die Rolle des Neuregulin-1/ErbB Signalsystems in der Entwicklung von Neuralleistenzellen und sich daraus entwickelnden Komponenten des peripheren Nervensystems (sympathisches Nervensystem und periphere Glia) untersucht. Neuregulin-1 Signale werden in Neuralleistenzellen und ihren Gliaderivaten durch ErbB2/ErbB3 Rezeptor-Heterodimere übertragen. Mit Hilfe von Mäusen mit gezielter Mutation (knock-out) des Neuregulin-1, ErbB2 oder ErbB3 Gens wurde gezeigt, daß Neuregulin-1/ErbB2/3 Signale die Migration sympathogener Neuralleistenzellen steuern. Mutante Tiere entwickeln daher eine hochgradige Hypoplasie des sympathischen Nervensystems. Neuregulin-1 Signale kontrollieren darüber hinaus die Entwicklung von Schwann Zellen. Die Unterbrechung des Neuregulin-1/ErbB2/3 Signalwegs in mutanten Mäusen führt zum Verlust von Schwann Zellen während der Embryogenese. Es wurde außerdem gezeigt, daß der Transkriptionsfaktor Sox10 die Expression von ErbB3 in Neuralleistenzellen kontrolliert. Sox10 und ErbB3 Mutanten besitzen daher übereinstimmende Defekte in der Neuralleistenzellentwicklung. Neben den ErbB3-abhängigen Funktionen von Sox10 wurde eine ErbB3-unabhängige Schlüsselfunktion von Sox10 bei der Differenzierung von Neuralleistenzellen zu peripherer Glia identifiziert. Das Neuregulin-1/ErbB2/3 Signalsystem und der Transkriptionsfaktor Sox10 besitzen also gemeinsam zentrale Funktionen in der Entwicklung peripherer Glia, steuern diesen Prozess aber über unterschiedliche Mechanismen und während unterschiedlicher Entwicklungsphasen. Sox10, ErbB2 und ErbB3 mutante Mäuse entwickeln neben dem Verlust von Schwann Zellen eine sekundäre Degeneration begleitender sensorischer und motorischer Neurone. Dies zeigt, daß periphere Glia Signale generiert, die essentiell sind für Integrität und Überleben begleitender Neurone. / Neuregulins (NDF, heregulin, GGF ARIA, or SMDF) are EGF-like growth and differentiation factors that signal through tyrosine kinase receptors of the erbB family. The neuregulin-1 proteins and their receptors play essential roles during embryonic development and in the adult. Functions of the neuregulin/erbB signaling system in developing neural crest cells and their derivatives (sympathetic nervous system, peripheral glial cells) were analyzed in mice with targeted mutations in the erbB2, erbB3, or neuregulin-1 genes. All three mutations cause severe hypoplasia of the primary sympathetic ganglion chain, and migration of sympathogenic neural crest cells to their target sites, where they differentiate into sympathetic neurons, depends on neuregulin-1 and its receptors. Neuregulin-1 signals are also essential for the development of Schwann cells. As a consequence, mice with targeted mutations in the neuregulin-1/erbB signaling system completely lack Schwann cells. Moreover, the HMG-box transcription factor sox10 is shown to control expression of erbB3 in neural crest cells. In accordance, sox10 and erbB3 mutant mice share phenotypes in the developing neural crest. Additionally, a novel, erbB3-independent developmental function of sox10 was identified: Sox10 is a key regulator for glial fate determination in undifferentiated neural crest cells. Thus, the transcription factor sox10 and the neuregulin-1/erbB signalling system both serve critical functions during development of peripheral glial cells. However, they act via different cellular mechanisms and during different developmental stages. At later developmental stages lack of peripheral glial cells in sox10, erbB2 and erbB3 mutant mice results in a severe degeneration of sensory and motor neurons. The comparison of the mutant phenotypes demonstrates, that peripheral glial cells generate essential signals for the survival and maintenance of accompanying neurons.

Notre laboratoire a démontré que la capacité proinflammatoire du vascular endothelial growth factor (VEGF-A165) implique la synthèse endothéliale du facteur d’activation plaquettaire (PAF) via l’activation du récepteur tyrosine kinase homodimérique VEGFR-2/R-2. La synthèse du PAF requiert l’activation de la p38 MAPK et p42/44 MAPK qui activent la phospholipase A2 secrétée de type V (sPLA2-V). Nous avons découvert que la synthèse aigue de prostacycline (PGI2) induite par le VEGF-A165 requiert l’activation des récepteurs hétérodimériques VEGFR-1/R-2. L’activation sélective des récepteurs du VEGF peut donc agir comme balance dans la synthèse de facteurs pro-(PAF) et anti-(PGI2) inflammatoire. Cependant, les tyrosines impliquées dans la transphosphorylation de VEGFR-2/R-2 menant à la synthèse du PAF sont inconnues. Par mutagenèse dirigée, nous avons effectué des transfections transitoires de cellules endothéliales avec des plasmides codant pour le VEGFR-2 dont les tyrosines ciblées ont été remplacées de façon séquentielle par une phénylalanine. Un vecteur vide pcDNA a été utilisé comme contrôle négatif. La stimulation des cellules endothéliales de l’aorte bovine (BAEC) transfectées avec le VEGF-A165 (1nM) pendant 15 minutes augmente la synthèse du PAF de 300%, laquelle était similaire dans les BAEC non transfectées. Dans les BAEC transfectées avec les vecteurs pcDNA codant pour les mutations Y801F, Y1059F, Y1175F et Y1214F, nous avons observé une réduction de 54, 73, 68, et 57% respectivement de la synthèse du PAF induite par le VEGF par rapport au pcDNA témoin. Nos résultats apportent un nouvel aperçu sur le mécanisme par lequel le VEGF induit la synthèse du PAF qui est connu pour sa contribution dans l’activité pro-inflammatoire du VEGF. / Vascular endothelial growth factor (VEGF) inflammatory effects require acute platelet-activating factor (PAF) synthesis by endothelial cells (EC). We reported that VEGF-mediated PAF synthesis involves the activation of the homodimeric tyrosine kinase receptor VEGFR-2/R-2 which is leading to p38 and p42/44 mitogen-activated protein kinases (MAPKs) and secreted group V phospholipase A2 (sPLA2-V) activation. We also reported that VEGF-A165-mediated prostacyclin (PGI2) synthesis requires VEGFR-1/R-2 heterodimeric receptor activation. Selective activation of VEGF receptors can thus act as a balance in the synthesis of pro-(PAF) and anti-(PGI2) inflammatory factors. It is unknown which VEGFR-2 tyrosine phosphorylation site(s) contribute(s) to PAF synthesis. Bovine aortic endothelial cells (BAEC) were transfected with pcDNA vectors encoding for native VEGF receptor-2 (VEGFR-2) cDNA, or tyrosine phosphorylation sites mutated into phenylalanine (Y801F), (Y1059F), (Y1175F), (Y1214F), and an empty pcDNA vector was used as negative control. Treatment of pcDNA-transfected BAEC with VEGF-A165 (1nM) for 15 minutes increased PAF synthesis by 300%, which was similar to VEGF-mediated PAF synthesis in untransfected BAEC. In BAEC transfected with pcDNA vectors encoding mutated Y801F, Y1059F, Y1175F or Y1214F VEGFR-2 cDNA, we observed a marked reduction of VEGF-mediated PAF synthesis by 54, 73, 68 and 57% respectively as compared to pcDNA-transfected BAEC. Our current data provide novel insight on the mechanisms by which VEGF promotes endothelial PAF synthesis which is known to contribute to VEGF pro-inflammatory activities.

No description available.